ADMA Bio reported Q2 2026 financial results, showing strong growth in ASCENIV revenue and GAAP net income. The company reiterated FY2026 guidance and announced real-world evidence highlighting clinical improvements in treated patients.
ADMA Bio reported Q2 2026 financial results, showing strong growth in ASCENIV revenue and GAAP net income. The company reiterated FY2026 guidance and announced real-world evidence highlighting clinical improvements in treated patients.